Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal

• If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month.
• Ouro Medicine is developing drugs for autoimmune diseases such as lupus and rheumatoid arthritis. 
• Gilead is most known for its HIV drug franchise.

Gilead Sciences (GILD) is reportedly looking to expand its offerings in the autoimmune disease segment with the acquisition of privately-held biotech Ouro Medicine for up to $2 billion.

The Financial Times reported on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.

As per the report, the talks are at an advanced stage and a deal could be announced in the coming days, though the terms might change.  

If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month in order to gain full access to a new multiple myeloma cell therapy.

Gilead’s Acquisition Approach

“...we are carefully strengthening our early-stage pipeline to position Gilead well for the long term, typically investing about $1 billion annually in smaller licensing deals, partnerships, and acquisitions. Additionally, we are proactive and disciplined in our approach to later-stage acquisitions that support our strategic goals and add new growth opportunities,” the company said during its fourth quarter earnings call in February.

“We're very ready, we're very proactive and disciplined, but we may not have the urgency of other companies in this sector, so we're gonna be disciplined around that. But I would say that we very much want to continue to add to our pipeline with appropriate, M&A over the course of the coming years as well.”

Gilead is most known for its HIV drug franchise. In 2025, the company reported a 6% in HIV product sales to $20.8 billion. The HIV product segment sales accounted for about 72% of the company’s overall product sales in the period.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around GILD stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.

GILD stock has gained 29% over the past 12 months. 

Read More: Why Is Estee Lauder Stock Down Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.